Development of a stratification tool to identify pancreatic intraductal papillary mucinous neoplasms at lowest risk of progression
Male
Risk
EMC MM-04-20-01
EMC NIHES-02-65-01
Middle Aged
3. Good health
Cohort Studies
Pancreatic Neoplasms
03 medical and health sciences
0302 clinical medicine
EMC MM-03-49-01
Disease Progression
Humans
Female
Prospective Studies
Pancreatic Cyst
Identifying Pancreatic Intraductal Papillary Mucinous Neoplasms at Low Risk of Progression
Pancreas
Aged
Carcinoma, Pancreatic Ductal
DOI:
10.1111/apt.15440
Publication Date:
2019-08-20T01:05:11Z
AUTHORS (11)
ABSTRACT
Because most pancreatic intraductal papillary mucinous neoplasms (IPMNs) will never become malignant, currently advocated long-term surveillance is low-yield for individuals.To develop a score chart identifying IPMNs at lowest risk of developing worrisome features or high-risk stigmata.We combined prospectively maintained cyst databases three academic institutions. Patients were included if they had presumed side-branch IPMN, without stigmata baseline (as defined by the 2012 international Fukuoka guidelines), and followed ≥ 12 months. The endpoint was development one more during follow-up. We created multivariable prediction model using Cox-proportional logistic regression analysis performed an internal-external validation.875 patients included. After mean follow-up 50 months (range 12-157), 116 (13%) developed stigmata. final size (HR 1.12, 95% CI 1.09-1.15), multifocality 1.49, 1.01-2.18), ever having smoked 1.40, 0.95-2.04), history acute pancreatitis 2.07, 1.21-3.55), extrapancreatic malignancy 1.34, 0.91-1.97). validation, good discriminative ability (C-statistic 0.72 in Mayo cohort, 0.71 Columbia 0.64 Erasmus cohort).In side branch baseline, Dutch-American Risk stratification Tool (DART-1) successfully identifies lesions low
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (53)
CITATIONS (24)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....